Close Menu

NEW YORK – Myriad Genetics said it has submitted a supplementary premarket approval application to the US Food and Drug Administration for myChoice CDx as a companion diagnostic for olaparib (AstraZeneca/Merck's Lynparza) in combination with bevacizumab (Genentech's Avastin).

In January, the FDA accepted AstraZeneca and Merck's supplementary new drug application for the olaparib/bevacizumab combination and granted it priority review for the maintenance treatment of advanced ovarian cancer patients who are responding to first-line platinum chemotherapy with bevacizumab.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.